Flora Peyvandi/X
Apr 12, 2026, 13:26
Flora Peyvandi: What Can Be Alternative to Warfarin
Flora Peyvandi, Professor of Internal Medicine at the University of Milan and former President of ISTH, shared a post on X about a recent article by James H. Morrissey, published in ASH Publications:
“Warfarin may be more effective in high-thrombotic-risk conditions because it lowers prothrombin levels, a clotting protein with a long half-life (60–72 hours).
This long half-life helps smooth out fluctuations in drug effect over time.”
Title: A different alternative to warfarin?
Author: James H. Morrissey
Read the Full Article on ASH Publications
More posts featuring Flora Peyvandi on Hemostasis Today.
-
Oct 16, 2026, 16:22Shannon Farmer: Driving Patient Blood Management Forward in Australia and New Zealand
-
Oct 16, 2026, 16:01Obi Light Ogbonnia: The Greatest Reward Is Changing Lives, Not Winning Awards
-
Oct 16, 2026, 15:18Carmine Liberatore: Limited Accuracy of VTE Risk Scores in Multiple Myeloma
-
Oct 16, 2026, 14:55Alex Borstein and the Bleeding Phenotype of Hemophilia A Carriers
-
Oct 16, 2026, 13:59Aya Akmal Amin: Antiphospholipid Syndrome Management and Risk Stratification
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A